Open Meeting Announcement - External Infusion Pumps Proposed Local Coverage Determination (LCD)

On Wednesday, August 27, 2025 at 12 pm ET, the Durable Medical Equipment Medicare Administrative Contractors (DME MACs) will host a virtual public meeting to solicit stakeholder comments for the following proposed LCD:

External Infusion Pumps (DL33794) - Proposing to (1) expand coverage for blinatumomab to adult and pediatric beneficiaries one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy; (2) clarify the existing blinatumomab criteria to include the age qualifier of "one month and older" to be consistent with the clinical literature and FDA prescribing information; (3) update coverage criteria for infusion-based therapy for the treatment of motor control symptoms associated with Parkinson’s Disease that are inadequately controlled by non-infusion-based therapy; and, (4) add code J7356 to the HCPCS array.

This virtual meeting is for the oral presentation of comments and for stakeholders interested in listening to the comments.

Registration for the virtual meeting opens July 24, 2025 and is available online at: https://attendee.gotowebinar.com/register/2726257121530356828

Registration will remain open until the day of the virtual open meeting.

  • Stakeholders interested in presenting oral comments during the virtual open meeting must submit early registration by Wednesday, August 6, 2025 at 5pm ET. (After this date and time, the meeting registration will no longer include the option to present oral comments.) 
  • Stakeholders interested in listening to the comments may either register (before the open meeting date) or choose to solely dial into the meeting. By registering for the meeting, stakeholders can view the web presentation while the meeting takes place.

Note: The DME MACs publish the open meeting recording to their contractor websites; therefore, all stakeholders will be able to view the recording regardless of whether they attended the meeting (via web and/or phone).

The following teleconference information is available for those who choose to dial into the meeting.

Conference dial-in number:

US Toll: 1 866 901 6455
Phone conference ID: 563 882 288

Note: For all who register, teleconference information will also be emailed to you.

Stakeholders who indicate, in their registration, that they intend to present oral comments:

  • By registering, you consent to your oral comments being recorded at the virtual meeting. We ask that comments from the same organization/manufacturer be consolidated and presented by a single representative or spokesperson. Therefore, while multiple people from an organization or manufacturer may register to attend the open meeting, we ask that only one person identify an intent to present oral comments when completing early registration.
  • Any material (such as slides) you intend to present during the virtual open meeting must be sent to DMEOpenMeeting@noridian.com by Wednesday, August 13, 2025 at 5 pm ET. In the body of the email, please include the name of the presenter and the represented organization, if applicable. If you submit material in the form of a slide deck, please ensure the slides are compatible with PowerPoint and are formatted in widescreen (16:9 aspect ratio).
  • You must not include any protected health information (PHI) or personally identifiable information (PII) in your oral comments or presentation material.

The amount of time allotted for oral commenters' presentations will be determined by the number of oral commenters registered. Prior to the virtual meeting, information regarding the allotted speaking time will be provided to those who registered to present oral comments.

IMPORTANT REMINDERS: Suppliers and clinicians are cautioned not to make any changes based upon information contained in a proposed LCD. The content of a proposed LCD may be revised based upon the written comments received during the comment period. In order for oral comments to be included in the review and consideration of the proposed LCD, these comments must also be submitted in writing through the formal comment process during the comment period. When all written comments have been reviewed, revisions will be considered. Information related to the written comment process is available at Proposed Local Coverage Determinations (LCDs) Released for Comment - External Infusion Pumps and Knee Orthoses.

Refer to each DME MAC website for additional information, including access to the proposed LCD.

Thank you for your participation in our policy development process.

Smitha M. Ballyamanda, MD, CAQSM
Medical Director, DME MAC Jurisdiction A
Noridian Healthcare Solutions, LLC

Sunil V. Lalla, MD, FACS, CPC
Medical Director, DME MAC Jurisdiction B
CGS Administrators, LLC

Robert D. Hoover, Jr., MD, MPH, FACP
Medical Director, DME MAC Jurisdiction C
CGS Administrators, LLC

Angela S. Jenny, DO, DABFM
Medical Director, DME MAC, Jurisdiction D
Noridian Healthcare Solutions, LLC

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )